Long-term stability of morphine and bupivacaine mixture for spinal use.
From clinical studies it has been proven that morphine in combination with bupivacaine is applicable in cancer pain. The availability of a ready to use parental dosage form of morphine and bupivacaine is comfortable for health care workers. Stability of a morphine or a bupivacaine preparation or a combination of both in a PVC cassette or polypropylene syringe for spinal use is examined in several studies. Apart from one study no data on long-term stability of morphine-bupivacaine mixture is available. A forced degradation study and a shelf-life study at room temperature (20-25 degrees C) were started on morphine hydrochloride 0.2 mg/ml and bupivacaine hydrochloride 7.5 mg/ml in 50 ml sterilized glass bottles type II. The results of the stability study showed that this mixture was stable up to 18 months at room temperature, whereafter morphine showed a slight degradation (5%) and bupivacaine remained stable.
Essink-Tjebbes
C M
CM
Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands.
Burger
D M
DM
Beelen
M
M
Wuis
E W
EW
Hekster
Y A
YA
D000701:Analgesics, Opioid / Q000032:analysis*; D000779:Anesthetics, Local / Q000032:analysis*; D002045:Bupivacaine / Q000032:analysis*; D002851:Chromatography, High Pressure Liquid; D004338:Drug Combinations; D004355:Drug Stability; D006863:Hydrogen-Ion Concentration; D007278:Injections, Spinal; D009020:Morphine / Q000032:analysis*; D019999:Pharmaceutical Solutions; D013696:Temperature
D000701:Analgesics, Opioid; D000779:Anesthetics, Local; D004338:Drug Combinations; D019999:Pharmaceutical Solutions; D009020:Morphine; D002045:Bupivacaine